Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2020.10958 mmr-21-03-1517 Articles Role of downregulated ADARB1 in lung squamous cell carcinoma WangXiang 1 2 RenXinxin 3 LiuWanli 1 2 ChenXi 1 2 WeiJie 1 2 GongZhicheng 1 2 YanYuanliang 1 2 XuZhijie 4 Department of Pharmacy, Xiangya Hospital, Central South University, P.R. China National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, P.R. China Center for Molecular Medicine, Xiangya Hospital, Key Laboratory of Molecular Radiation Oncology of Hunan Province, Central South University, P.R. China Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China Correspondence to: Dr Yuanliang Yan, Department of Pharmacy, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, P.R. China, E-mail: yanyuanliang@csu.edu.cn Dr Zhijie Xu, Department of Pathology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, P.R. China, E-mail: xzj1322007@csu.edu.cn 032020 23012020 21 3 1517 1526 10072019 17122019 Copyright: © Wang et al. 2020 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Non-small cell lung cancer (NSCLC) is prevalent worldwide. Lung squamous cell carcinoma (LUSC) is one of the main subtypes of NSCLC yet, currently, few biomarkers are available for the diagnosis of LUSC. The present study aimed to investigate the expression and role of adenosine deaminase RNA specific B1 (ADARB1) in lung squamous cell carcinoma (LUSC). Integrative bioinformatics analysis was used to identify the effects of ADARB1 expression on the occurrence and prognosis of LUSC. The expression of ADARB1 was further examined by immunohistochemistry (IHC). Bioinformatics analysis suggested that ADARB1 was downregulated in LUSC, serving as a potential tumor suppressor, and these results were verified by IHC performed on a lung cancer tissue array. Clinical studies suggested that ADARB1 expression and methylation levels were significantly associated with patient characteristics in LUSC. Moreover, ADARB1 global methylation levels were upregulated in LUSC tissues compared with normal lung tissues. Higher methylation levels of cg24063645 were associated with shorter overall survival time of patients with LUSC. A negative correlation was identified between ADARB1 and epidermal growth factor receptor (EGFR) expression in LUSC. Using the Gene Expression Omnibus database, it was suggested that the expression of ADARB1 in LUSC was significantly different compared with that in lung adenocarcinoma. Furthermore, protein-protein interactions were studied and a biological process annotation analysis was conducted. The present study suggested that ADARB1 was downregulated in LUSC; therefore, ADARB1 may serve as a specific biomarker and a potential therapeutic target for LUSC.

 adenosine deaminase RNA specific B1 expression methylation survival therapeutics Introduction

Lung cancer was the leading cause of cancer-related death worldwide in 2015 and non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancer cases (1). Lung squamous cell carcinoma (LUSC) is one of the main subtypes of NSCLC. A previous study indicated that the 5-year overall survival (OS) rate for patients with LUSC is 17.7% due to late diagnosis (2). In addition, there have been limited opinions for LUSC treatment compared to lung adenocarcinoma (LUAD) although progress has been made in the treatment of NSCLC (3–5). The reason is partly because there are more molecular abnormalities for LUSC in the discoidin domain receptor tyrosine kinase 2 and fibroblast growth factor receptor 1 genes (6). Early identification of the disease would reduce the mortality rate of patients with LUSC who could benefit most from effective therapies (7). However, few biomarkers are currently available for the effective diagnosis of LUSC, which would enable patients to receive timely treatment (8). Thus, identifying novel target molecules is essential for improving the diagnosis and treatment of LUSC.

Adenosine deaminase RNA specific B1 (ADARB1) is a member of the adenosine deaminases acting on RNA (ADAR) family, which exhibit enzymatic editing activity in a process known as adenosine-to-inosine (A-to-I) editing (9). Recently, research has indicated an association between ADARB1 and cancer. A previous study reported that ADARB1, an indispensable marker in brain development and function, could inhibit the proliferation and progression of glioblastoma (10). In terms of esophageal squamous cell carcinoma, Chen et al (11) reported that ADARB1 induces apoptosis and suppresses tumor growth by editing insulin-like growth factor binding protein 7 mRNA. Additionally, ADARB1 can regulate exon 12A, an exon from the heterogeneous nuclear ribonucleoprotein L like transcript, to promote cancer cell survival (12). However, the relationship between ADARB1 and LUSC has not been investigated.

Therefore, the present study aimed to investigate the role of ADARB1 in LUSC. The results suggested that ADARB1 was downregulated in LUSC tissues and cell lines. The expression and methylation status of ADARB1 were significantly associated with clinical characteristics and prognosis. Additionally, the GSE10245 dataset (13), acquired from the Gene Expression Omnibus (GEO) (14) database, suggested that ADARB1 expression levels in LUSC were lower than in LUAD. Finally, functional enrichment analysis of ADARB1-associated co-expression genes was conducted and a protein-protein interaction (PPI) network was established. The results of the Gene Ontology (GO) analysis suggested that the main biological processes (‘metabolic process’ and ‘biological regulation’), cellular components (‘nucleus’) and molecular functions (‘protein binding’) were associated with ADARB1. In addition, ADARB1 expression was significantly related to the Kyoto Encyclopedia of Genes and Genomes (KEGG) terms ‘ubiquitin mediated proteolysis’ and ‘Wnt signaling pathway’.

 Materials and methods <sec> <title>Data acquisition and reanalysis using bioinformatics methods

Several bioinformatics web resources were used to reanalyze data concerning ADARB1 (Table SI). The Genome Mining (GE-mini) database was employed to examine gene expression profiles over a number of tissue types, including tumors (15). The Cancer Cell Line Encyclopedia (CCLE) project is a public database containing detailed genetic and pharmacological characterization of numerous cell lines (16). The GE-mini and CCLE databases were used to identify the expression profiles of ADARB1 in LUSC tissues and cell lines. Oncomine (17), University of Alabama Cancer Database (UALCAN) (18) and Gene Expression Profiling Interactive Analysis (GEPIA) (19) were used to verify the results. The GEPIA database was also used to identify the Pearson correlation between ADARB1 and epidermal growth factor receptor (EGFR) in LUSC.

Wanderer is an interactive platform, which provides human cancer gene expression and DNA methylation data. This platform was used to evaluate the relationship between ADARB1 levels and patient clinical characteristics (20). DiseaseMeth (version 2.0) is a human disease methylation database, which was used to analyze ADARB1 global methylation levels in LUSC (21). The MethSurv tool was used to analyze the association between ADARB1 methylation and LUSC prognosis by using the mean value to dichotomize methylation profiles of patients (22). The GSE10245 dataset, downloaded from the GEO database, provided ADARB1 expression profiles in LUAD and LUSC samples.

A dataset LUSC (TCGA, Nature 2012) (23) from the cBioportal (24) web tool was used to obtain gene co-expression data for ADARB1 in LUSC. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (25) and Cytoscape software (26) were then used to build a PPI network of the co-expression genes. Moreover, GO and KEGG (27) pathway analyses were conducted, using the Web-based Gene Set Analysis Toolkit (WebGestalt) (28) and the Database for Annotation, Visualization and Integrated Discovery (DAVID) (29) bioinformatics resources, respectively.

 Immunohistochemistry (IHC) analysis of a lung cancer tissue array

The LUC481 lung cancer tissue array and information regarding the cancer subtypes of the array were obtained from Fanpu Biotech, Inc. IHC was performed using the Histomouse SP Broad Spectrum DAB kit (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Following antigen retrieval which was performed by microwaving in 10 mM citrate buffer (pH 6.0), paraffin-embedded sections were immunostained using a streptavidin peroxidase procedure. After blocking the samples with 3% bovine serum albumin (100 ml, SW3015, Beijing Solarbio Science & Technology Co., Ltd.) for 15 min at room temperature, the primary antibody against ADARB1 (cat. no. sc-73409, Santa Cruz Biotechnology, Inc., 1:100 dilution) was added and samples were incubated at 4°C overnight. Following washing with PBS, the horseradish peroxidase (HRP)-conjugated polymer second antibody (PV-6000, OriGene Technologies, Inc.) was added and samples were incubated for 30 min at room temperature. The signal was examined using a 3,3′-diaminobenzidine solution. Subsequently, four fields of view of the stained sections were independently observed in a light microscope at magnifications of ×4 and ×20 by two pathologists. The staining intensity of each protein was divided into four grades (intensity scores): 0 (negative), 1 (weak brown), 2 (moderate brown) and 3 (strong brown). The percentage of positive cells was scored as 0 (≤10%), 1 (11–25%), 2 (26–50%), 3 (51–75%) and 4 (>75%) (30). The final staining score was calculated using the following formula: Intensity score × percentage score (1). A final score >1 was defined as high expression and final scores ≤1 were defined as low expression.

 Statistical analysis

Statistical analyses were performed using SPSS software (version 12.0; SPSS, Inc.). The data are presented as the mean ± SD. A paired-sample t-test was used for normally distributed and continuous variables were statistically analyzed by one-way analysis of variance with LSD post hoc test. Multivariate analysis was accomplished utilizing the Cox regression model to identify independence of accepted clinical parameters and the ordinal variables were tested with Kruskall-Wallis test followed by Dunn's post-hoc test. The Kaplan-Meier analysis was statistically tested by the log-rank method. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>ADARB1 is downregulated in LUSC tissues and cell lines

By analyzing several databases, the transcriptional levels of ADARB1 in LUSC tissues and cell lines were compared with those observed in normal lung tissue and cells. GE-mini analysis revealed that ADARB1 mRNA expression was significantly decreased in LUSC tissues (Fig. 1A). The CCLE database suggested that ADARB1 mRNA expression was significantly downregulated in ~10 LUSC cell lines compared with immortalized lung epithelial cell lines (P=0.001; Fig. 1B). To further investigate these observations, the Oncomine, UALCAN and GEPIA databases were employed. Analysis with all three databases suggested that ADARB1 was expressed at significantly lower levels in LUSC tissues compared with in normal lung tissues (Fig. 1C-E). Furthermore, IHC analysis, based on a lung cancer array containing 16 normal samples, 12 LUSC samples and 10 LUAD samples, suggested that ADARB1 was significantly downregulated in LUSC samples compared with normal lung samples (P=1.58×10−8; Fig. 2A and B). In summary, the downregulation of ADARB1 expression levels in LUSC tissues and cell lines suggested that ADARB1 may be a promising anti-oncogene in LUSC.

 ADARB1 could be used for the identification of LUSC and LUAD

The results of the IHC analysis further suggested that ADARB1 was downregulated in LUAD tissues compared with normal lung tissues, which was consistent with our previous study (P=0.024; Fig. 2A and B) (31). Furthermore, ADARB1 expression levels were significantly lower in LUSC tissues than in LUAD tissues (P=0.025; Fig. 2A and B). Subsequently, the GSE10245 dataset, obtained from GEO, suggested that ADARB1 was expressed at a lower level in LUSC compared with LUAD (P=0.031; Fig. 3A). Furthermore, this significant difference was verified by the CCLE database (P=0.008; Fig. 3B). Therefore, these results suggested that ADARB1 expression profiles may serve as indicators for the clinical diagnosis of LUSC and LUAD.

 Relationship between ADARB1 expression and the clinical characteristics of patients with LUSC

The effects of ADARB1 expression on the clinical characteristics of patients with LUSC were examined. Clinical data were downloaded from the Wanderer database, and the clinical characteristic parameters are summarized in Table I. The expression of ADARB1 was significantly associated with the pathologic N stage (P=0.045), pathologic M stage (P=0.012) and tobacco smoking history indicator (P=0.008). Furthermore, multivariate analysis of the clinical data suggested that the pathologic N stage (P=0.020), pathologic M stage (P=0.003) and tobacco smoking history indicator (P=0.017) were independently associated with ADARB1 expression in patients with LUSC (Table II).

 ADARB1 methylation is related to the clinical characteristics of patients with LUSC

The ADARB1 global methylation levels in LUSC were evaluated using the DiseaseMeth database. ADARB1 displayed significantly higher levels of methylation in LUSC samples compared with in normal lung samples (P=1.62×10−12; Fig. 4A). The highest methylation value of cg24063645 in ADARB1 was identified using the Wanderer and MethSurv databases (P=3.60×10−19; Fig. 4B; Table SII). Subsequently, the association between cg24063645 methylation and the clinical characteristics of patients with LUSC was analyzed. The methylation of cg24063645 of ADARB1 was significantly associated with the Karnofsky score of patients with LUSC (P=0.025; Table III). Moreover, higher methylation levels of cg24063645 of ADARB1 were associated with shorter OS of patients with LUSC (P=0.044; Fig. 4C). Therefore, the results suggested that ADARB1 methylation levels may serve a role in the prognosis of patients with LUSC.

 ADARB1 expression is negatively correlated with EGFR expression in LUSC tissues

EGFR is an oncogenic driver that contributes to the activation and development of lung cancer (7). Previous studies have indicated a poor correlation between EGFR expression and the overall response rate in lung cancer, particularly in LUSC (7,32,33). The GEPIA database was employed to evaluate the relationship between ADARB1 and EGFR. A negative correlation between ADARB1 and EGFR transcript levels in tissues of patients with LUSC was identified (P=7.80×10−6; R=−0.16; Fig. 5), which suggested that ADARB1 acted as an anti-cancer gene and might be linked to EGFR.

 Network analysis of genes co-expressed with ADARB1

To further investigate the biological function of ADARB1, a functional enrichment analysis of its associated co-expressed genes was conducted. Firstly, 14,102 genes co-expressed with ADARB1 in LUSC were identified using the cBioPortal database, and a volcano plot was generated to display the association between groups with altered and unaltered ADARB1 expression (Fig. 6A). Based on the criteria of |log ratio|>0.3 and P<0.05, 158 ADARB1-associated, co-differentially expressed genes (co-DEGs) were identified (Table SIII). A protein-protein interaction network was generated using the STRING database and Cytoscape software (Fig. 6B). Moreover, WebGestalt was used to analyze GO terms (Fig. 6C) and indicated that the main biological processes of the co-DEGs were primarily enriched in ‘metabolic process’ and ‘biological regulation’. Moreover, Gan et al (34) reported that ADARB1 participated in the regulation of pancreatic islet and β-cell function. Furthermore, deficient or hyperactive ADARB1 expression is associated with a number of human diseases, including immunological disorders, amyotrophic lateral sclerosis, epilepsy and cancer (35). Therefore, it was speculated that ADARB1 might serve a role in LUSC via metabolic processes and biological regulation. In addition, for cellular components and molecular functions, the co-DEGs were primarily enriched in ‘nucleus’ and ‘protein binding’, respectively. Finally, KEGG pathway enrichment was analyzed using the DAVID database, and ‘ubiquitin mediated proteolysis’ and ‘Wnt signaling pathway’ were identified as significantly enriched pathways related to ADARB1 expression (Table SIV).

 Discussion

The present study was conducted to evaluate the use of ADARB1 as a potential biomarker for patients with LUSC. To the best of our knowledge, the present study was the first to use bioinformatics methods to suggest that ADARB1 was downregulated in LUSC tissues and cell lines. Moreover, the expression of ADARB1 in LUSC was significantly different to that in LUAD. In addition, the global methylation levels of ADARB1 were upregulated in LUSC and a higher methylation value of cg24063645 was related to a shorter OS in patients with LUSC.

A-to-I RNA editing is a post-transcriptional modification mediated by the ADAR family, which is comprised of three members, ADAR1, ADARB1 and ADAR3 (36,37). The expression levels of ADARB1 determine the RNA editing activity at a number of A-to-I sites, which are involved in several diseases, including amyotrophic lateral sclerosis, autism and Fragile-X Syndrome (38). Recently, several studies have indicated that ADARB1 participates in tumorigenesis as a cancer suppressor gene, which is consistent with the results of the present study. By analyzing the influence of A-to-I RNA modification on cancer progression, Fritzell et al (39) reported that ADARB1 was expressed at low levels in glioblastoma, indicating that ADARB1 downregulation could induce malignant phenotypes. Additionally, using next-generation sequencing transcriptomics, Chan et al (40) reported that ADARB1 contributed to inhibitory mechanisms in gastric cancer via its catalytic deaminase. However, Altadill et al (41) demonstrated that ADARB1 was upregulated in endometrial cancer, and the increased expression was positively associated with disease aggression, suggesting that ADARB1 functions as an oncogene in endometrial cancer. The inconsistency between the observations of these aforementioned studies and the present study may be due to the diverse pathological states of different diseases; therefore, further investigation is required.

ADARB1 is a therapeutic target in a number of human diseases. Uchida et al (42) reported a significant increase in ADAR2-dependent A-to-I editing at the glutamate ionotropic receptor AMPA type subunit R/G, 5-hydroxytryptamine 2c receptor D and COPI coat complex-α I/V sites, which suggested that ADARB1 was a regulator of neuropathic pain after peripheral nerve injury and could be used as a target for the treatment of neuropathic pain. In addition, Galeano et al (43) reported that ADARB1 could inhibit glioblastoma growth by the regulation of the cell division cycle 14B/S-phase kinase associated protein 2/p21/p27 axis; therefore, ADARB1 or its substrates represented suitable targets for the treatment of glioblastoma. In the present study, ADARB1 was significantly downregulated in LUSC and was associated with clinical characteristics of patients with LUSC. Furthermore, the hypermethylation of ADARB1 was related to the poor prognosis of patients with LUSC. Therefore, it was speculated that ADARB1 may represent a potential target for the treatment of LUSC; however, this requires further investigation.

LUSC and LUAD are the two main subtypes of NSCLC, and the accurate differentiation of LUSC and LUAD is important for therapy stratification (44). Although p40 is regarded as the gold standard for the differentiation of LUSC and LUAD by the World Health Organization and the European Society for Medical Oncology (45–47), the identification of further biomarkers is required for distinguishing LUSC from LUAD. At present, numerous immune markers have been reported for the differentiation of LUSC and LUAD, including NK2 homeobox 1, napsin A, keratin 5 and p63. Kriegsmann et al and van Zyl et al (48,49) reported that all four aforementioned markers were differentially expressed in LUSC and LUAD, and could therefore be used as biomarkers for the two cancer subtypes. By immunohistochemistry and western blotting, Wang et al (50) reported that the expression of the transcriptional co-factor tafazzin was associated with subtypes of LUSC and LUAD. Additionally, spermatogenesis associated serine rich 2, which is highly expressed in both LUSC and LUAD, displayed significantly higher expression in LUSC than LUAD, and thus, could be used as a marker to discriminate between the two subtypes (51,52). Similarly, in the present study, ADARB1 expression was significantly higher in LUAD tissues and cell lines compared with in LUSC tissues. Therefore, the present study suggested that ADARB1 might be used to distinguish between LUSC and LUAD.

EGFR has been demonstrated to be a driving factor in various types of cancer. A previous study indicated that, following phosphorylation on a regulatory tyrosine, EGFR can be activated in a ligand-dependent or -independent manner to induce tumor progression (53). Additionally, EGFR has been reported to be upregulated in a number of different types of cancer and has been associated with cancer metastasis, drug resistance, poor prognosis and lower survival rates (54). Moreover, the combination of aberrantly expressed EGFR and transforming growth factor (TGF)-α secretion by NSCLC cells can form a TGF-α-EGFR autocrine ring, which promotes tumor development (55,56). EGFR can also activate the downstream PI3K/Akt/mTOR signaling pathway, leading to cell growth and proliferation during NSCLC (57). The present study identified a negative correlation between ADARB1 and EGFR expression in LUSC. Thus, it was hypothesized that ADARB1 could disturb the EGFR carcinogenic effect via metabolic processes and biological regulation in LUSC. This observation suggested that ADARB1 might act as an anti-oncogene by influencing EGFR expression; therefore, ADARB1 may be a useful molecular target for LUSC therapeutics.

In summary, the expression and role of ADARB1 in LUSC was investigated using a novel bioinformatics method. The results suggested that ADARB1 may be an anti-oncogene, and that it could be a promising biomarker in the tumorigenesis of LUSC and development of novel therapeutics for the disease. Therefore, understanding the function and mechanisms of ADARB1 in LUSC would provide a useful basis for the diagnosis and treatment of LUSC.

 Supplementary Material Supporting Data Acknowledgements

Not applicable.

 Funding

The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 81703036, 81803035 and 81572946), the Fundamental Research Funds for the Central Universities of Central South University (grant no. 2019zzts345), the China Postdoctoral Science Foundation (grant no. 2017M610510) and the Youth Fund of Xiangya Hospital (grant no. 2017Q17).

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

ZX, YY and ZG conceived and designed the study. XW, YY and ZX developed the methodology. XR, XW and WL acquired the data. ZX, XW, YY, XC and JW analyzed and interpreted the data. XW, XR and ZX wrote, reviewed and revised the manuscript.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References YanYXuZQianLZengSZhouYChenXWeiJGongZIdentification of CAV1 and DCN as potential predictive biomarkers for lung adenocarcinomaAm J Physiol Lung Cell Mol Physiol316L630L643201910.1152/ajplung.00364.201830604627 ZhengHZhanYLiuSLuJLuoJFengJFanSThe roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implicationsJ Exp Clin Cancer Res37226201810.1186/s13046-018-0901-5302172176137883 BrahmerJReckampKLBaasPCrinòLEberhardtWEPoddubskayaEAntoniaSPluzanskiAVokesEEHolgadoENivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med373123135201510.1056/NEJMoa1504627260284074681400 HerbstRSBaasPKimDWFelipEPérez-GraciaJLHanJYMolinaJKimJHArvisCDAhnMJPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trialLancet38715401550201610.1016/S0140-6736(15)01281-726712084 ZugazagoitiaJPonceSPaz-AresLNecitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: A relevant step forward?Transl Lung Cancer Res595972016269585004758970 DrilonARekhtmanNLadanyiMPaikPSquamous-cell carcinomas of the lung: Emerging biology, controversies and the promise of targeted therapyLancet Oncol13e418e426201210.1016/S1470-2045(12)70291-723026827 YanYXuZHuXQianLLiZZhouYDaiSZengSGongZSNCA is a functionally low-expressed gene in lung adenocarcinomaGenes9piiE16201810.3390/genes901001629300342 TanWLJainATakanoANewellEWIyerNGLimWTTanEHZhaiWHillmerAMTamWLTanDSWNovel therapeutic targets on the horizon for lung cancerLancet Oncol17e347e362201610.1016/S1470-2045(16)30123-127511159 WangCZouJMaXWangEPengGMechanisms and implications of ADAR-mediated RNA editing in cancerCancer Lett4112734201710.1016/j.canlet.2017.09.03628974449 PengLZhangHSuYShenQDuCXieHLiHYanJShenZJiangWLipopolysaccharide enhances ADAR2 which drives Hirschsprung's disease by impairing miR-142-3p biogenesisJ Cell Mol Med2240454055201810.1111/jcmm.13652299564576111854 ChenYBLiaoXYZhangJBWangFQinHDZhangLShugartYYZengYXJiaWHADAR2 functions as a tumor suppressor via editing IGFBP7 in esophageal squamous cell carcinomaInt J Oncol50622630201710.3892/ijo.2016.382328035363 ChenYTChangIYLiuHMaCPKuoYPShihCTShihYHKangLTanBCTumor-associated intronic editing of HNRPLL generates a novel splicing variant linked to cell proliferationJ Biol Chem2931015810171201810.1074/jbc.RA117.001197297693106028967 KunerRMuleyTMeisterMRuschhauptMBunessAXuECSchnabelPWarthAPoustkaASültmannHHoffmannHGlobal gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypesLung Cancer633238200910.1016/j.lungcan.2008.03.03318486272 BarrettTEdgarRReannotation of array probes at NCBI's GEO databaseNat Methods5117200810.1038/nmeth0208-117b18235428 TangZLiCZhangKYangMHuXGE-mini: A mobile APP for large-scale gene expression visualizationBioinformatics33941943201728065896 BarretinaJCaponigroGStranskyNVenkatesanKMargolinAAKimSWilsonCJLehárJKryukovGVSonkinDThe cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivityNature483603607201210.1038/nature11003224609053320027 RhodesDRYuJShankerKDeshpandeNVaramballyRGhoshDBarretteTPandeyAChinnaiyanAMONCOMINE: A cancer microarray database and integrated data-mining platformNeoplasia616200410.1016/S1476-5586(04)80047-2150686651635162 ChandrashekarDSBashelBBalasubramanyaSAHCreightonCJPonce-RodriguezIChakravarthiBVSKVaramballySUALCAN: A portal for facilitating tumor subgroup gene expression and survival analysesNeoplasia19649658201710.1016/j.neo.2017.05.002287322125516091 TangZLiCKangBGaoGLiCZhangZGEPIA: A web server for cancer and normal gene expression profiling and interactive analysesNucleic Acids Res45W98W102201710.1093/nar/gkx247284071455570223 Diez-VillanuevaAMallonaIPeinadoMAWanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancerEpigenetics Chromatin822201510.1186/s13072-015-0014-8261138764480445 XiongYWeiYGuYZhangSLyuJZhangBChenCZhuJWangYLiuHZhangYDiseaseMeth version 2.0: A major expansion and update of the human disease methylation databaseNucleic Acids Res45D888D895201710.1093/nar/gkw112327899673 ModhukurVIljasenkoTMetsaluTLokkKLaisk-PodarTViloJMethSurv: A web tool to perform multivariable survival analysis using DNA methylation dataEpigenomics10277288201810.2217/epi-2017-011829264942 Cancer Genome Atlas Research NetworkComprehensive genomic characterization of squamous cell lung cancersNature489519525201210.1038/nature11404229607453466113 GaoJAksoyBADogrusozUDresdnerGGrossBSumerSOSunYJacobsenASinhaRLarssonEIntegrative analysis of complex cancer genomics and clinical profiles using the cBioPortalSci Signal6pl1201310.1126/scisignal.2004088235502104160307 SzklarczykDMorrisJHCookHKuhnMWyderSSimonovicMSantosADonchevaNTRothABorkPThe STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessibleNucleic Acids Res45D362D368201710.1093/nar/gkw93727924014 ReimandJIsserlinRVoisinVKuceraMTannus-LopesCRostamianfarAWadiLMeyerMWongJXuCPathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMapNat Protoc14482517201910.1038/s41596-018-0103-9306646796607905 KanehisaMFurumichiMTanabeMSatoYMorishimaKKEGG: New perspectives on genomes, pathways, diseases and drugsNucleic Acids Res45D353D361201710.1093/nar/gkw109227899662 WangJVasaikarSShiZGreerMZhangBWebGestalt 2017: A more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkitNucleic Acids Res45W130W137201710.1093/nar/gkx356284725115570149 Huang daWShermanBTLempickiRASystematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNat Protoc44457200910.1038/nprot.2008.21119131956 YangLLiuLXuZLiaoWFengDDongXXuSXiaoLLuJLuoXEBV-LMP1 targeted DNAzyme enhances radiosensitivity by inhibiting tumor angiogenesis via the JNKs/HIF-1 pathway in nasopharyngeal carcinomaOncotarget6580458172015257140204467403 WangXXuZRenXChenXWeiJLinWLiZOuCGongZYanYFunction of low ADARB1 expression in lung adenocarcinomaPLoS One14e0222298201910.1371/journal.pone.0222298314910246730894 ZhouSYanYChenXWangXZengSQianLWeiJYangXZhouYGongZXuZRoles of highly expressed PAICS in lung adenocarcinomaGene69218201910.1016/j.gene.2018.12.06430641222 XiaoDLuCZhuWHeQLiYFuCZhouJLiuSTaoYComparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancerOncotarget75904959057201610.18632/oncotarget.10011273221435312294 GanZZhaoLYangLHuangPZhaoFLiWLiuYRNA editing by ADAR2 is metabolically regulated in pancreatic islets and beta-cellsJ Biol Chem2813338633394200610.1074/jbc.M60448420016956888 LiZTianYTianNZhaoXDuCHanLZhangHAberrant alternative splicing pattern of ADAR2 downregulates adenosine-to-inosine editing in gliomaOncol Rep3328452852201510.3892/or.2015.390725873329 MerkleTMerzSReautschnigPBlahaALiQVogelPWettengelJLiJBStafforstTPrecise RNA editing by recruiting endogenous ADARs with antisense oligonucleotidesNat Biotechnol37133138201910.1038/s41587-019-0013-630692694 KuangLLvGWangBLiLDaiYLiYOverexpression of adenosine deaminase acting on RNA 1 in chordoma tissues is associated with chordoma pathogenesis by reducing miR125a and miR10a expressionMol Med Rep129398201510.3892/mmr.2015.3341256730444438963 HosakaTYamashitaTTeramotoSHiroseNTamaokaAKwakSADAR2-dependent A-to-I RNA editing in the extracellular linear and circular RNAsNeurosci Res1474857201910.1016/j.neures.2018.11.00530448461 FritzellKXuLDLagergrenJÖhmanMADARs and editing: The role of A-to-I RNA modification in cancer progressionSemin Cell Dev Biology79123130201810.1016/j.semcdb.2017.11.018 ChanTHQamraATanKTGuoJYangHQiLLinJSNgVHSongYHongHADAR-Mediated RNA editing predicts progression and prognosis of gastric cancerGastroenterology151637650.e10201610.1053/j.gastro.2016.06.04327373511 AltadillTDowdyTMGillKRequesAMenonSSMoiolaCPLopez-GilCCollEMatias-GuiuXCabreraSMetabolomic and Lipidomic profiling identifies the role of the RNA editing pathway in endometrial carcinogenesisSci Rep78803201710.1038/s41598-017-09169-2288218135562852 UchidaHMatsumuraSOkadaSSuzukiTMinamiTItoSRNA editing enzyme ADAR2 is a mediator of neuropathic pain after peripheral nerve injuryFASEB J3118471855201710.1096/fj.201600950R28126736 GaleanoFRossettiCTomaselliSCifaldiLLezzeriniMPezzulloMBoldriniRMassimiLDi RoccoCMLocatelliFGalloAADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axisOncogene329981009201310.1038/onc.2012.12522525274 ChenMLiuXDuJWangXJXiaLDifferentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancersOncotarget8133144201727863400 PlanchardDPopatSKerrKNovelloSSmitEFFaivre-FinnCMokTSReckMVan SchilPEHellmannMDPetersSMetastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol30863870201910.1093/annonc/mdy474 BishopJATeruya-FeldsteinJWestraWHPelosiGTravisWDRekhtmanNp40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinomaMod Pathol25405415201210.1038/modpathol.2011.17322056955 TravisWDBrambillaEBurkeAPMarxANicholsonAGIntroduction to The 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heartJ Thorac Oncol1012401242201510.1097/JTO.000000000000066326291007 KriegsmannKCremerMZgorzelskiCHarmsAMuleyTWinterHKazdalDWarthAKriegsmannMAgreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancerPathology51240245201910.1016/j.pathol.2018.11.00930798982 van ZylASchubertPTKoegelenbergCFNThe utility of TTF-1, napsin A, CK5 and p63 staining in the sub-classification of non-small cell carcinoma of the lungCytopathology30586591201910.1111/cyt.1274131206846 WangYHanYGuoZYangYRenTNuclear TAZ activity distinctly associates with subtypes of non-small cell lung cancerBiochem Biophys Res Commun509828832201910.1016/j.bbrc.2019.01.01230638934 HouJAertsJden HamerBvan IjckenWden BakkerMRiegmanPvan der LeestCvan der SpekPFoekensJAHoogstedenHCGene expression-based classification of non-small cell lung carcinomas and survival predictionPLoS One5e10312201010.1371/journal.pone.0010312204219872858668 TakamochiKOhmiyaHItohMMogushiKSaitoTHaraKMitaniKKogoYYamanakaYKawaiJNovel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lungBMC Cancer16760201610.1186/s12885-016-2792-1276810765041559 LipsickJA history of cancer research: Tyrosine kinasesCold Spring Harb Perspect Biol11piia035592201910.1101/cshperspect.a03559230709881 MartinezPPetersSStammersTSoriaJCImmunotherapy for the First-line treatment of patients with metastatic non-small cell lung cancerClin Cancer Res2526912698201910.1158/1078-0432.CCR-18-390430642913 LiuYJiangHZhouHYingXWangZYangYXuWHeXLiYLentivirus-mediated silencing of HOTAIR lncRNA restores gefitinib sensitivity by activating Bax/Caspase-3 and suppressing TGF-α/EGFR signaling in lung adenocarcinomaOncol Lett1528292838201829467862 Romero-VentosaEYBlanco-PrietoSGonzalez-PineiroALRodriguez-BerrocalFJPineiro-CorralesGPaez de la CadenaMPretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patientsSpringerplus4171201510.1186/s40064-015-0891-0259186814402684 GaoJQiuXXiGLiuHZhangFLvTSongYDownregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non-small cell lung cancerOncol Rep40197119842018301064506111570

Downregulation of ADARB1 in LUSC tissues and cell lines, as indicated by several databases. The expression of ADARB1 was analyzed by the (A) Genome Mining, (B) Cancer Cell Line Encyclopedia, (C) Oncomine, (D) University of Alabama Cancer Database and (E) Gene Expression Profiling Interactive Analysis databases. ADARB1, adenosine deaminase RNA specific B1; LUSC, lung squamous cell carcinoma; TPM, transcripts per million.

Downregulation of ADARB1 in the lung cancer tissue array. (A) Immunohistochemistry was used to examine the level of ADARB1 expression in a commercial lung cancer tissue array. (B) Protein levels of ADARB1 were significantly downregulated in the lung tissue of patients with LUSC or LUAD compared with normal lung tissue. ADARB1 expression was significantly decreased in LUSC tissues compared with LUAD tissue samples. ADARB1, adenosine deaminase RNA specific B1; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.

ADARB1 expression is significantly different between LUSC and LUAD. (A) Dataset GSE10245, obtained from Gene Expression Omnibus, suggested that ADARB1 was expressed at a lower level in LUSC compared with LUAD. (B) Difference in ADARB1 expression in LUSC and LUAD cell lines, as determined by Cancer Cell Line Encyclopedia analysis. ADARB1, adenosine deaminase RNA specific B1; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.

Methylation values of ADARB1 in patients with LUSC. (A) Global methylation of ADARB1 in LUSC samples compared with normal samples, using DiseaseMeth. (B) Heat map () acquired from MethSurv described the methylation sites of ADARB1 in LUSC. Red represents upregulation and blue represents downregulation. (C) Relationship between methylation values of cg24063645 of ADARB1 and overall survival time in LUSC. ADARB1, adenosine deaminase RNA specific B1; HR, hazard risk; LR, log rank; LUSC, lung squamous cell carcinoma.

ADARB1 expression is negatively correlated with EGFR expression in LUSC. The Gene Expression Profiling Interactive Analysis database identified an association between the transcript levels of ADARB1 and EGFR in tissues derived from patients with LUSC. ADARB1, adenosine deaminase RNA specific B1; EGFR, epidermal growth factor receptor; LUSC, lung squamous cell carcinoma; TPM, transcripts per million.

Functional enrichment analysis of ADARB1-associated co-DEGs in LUSC samples. (A) Volcano plot displayed the genes co-expressed with ADARB1 in LUSC (red represents upregulation, green represents downregulation and black is no change). (B) A protein-protein interaction network of ADARB1-associated co-DEGs was generated using the Search Tool for the Retrieval of Interacting Genes/Proteins database and Cytoscape software (square nodes represent hub genes, round nodes represent co-expression genes; the color represents the degree score; degree score <0.5 represent low values (colored yellow), degree score ≥0.5 represent high values (other colors). (C) Gene Ontology analysis of ADARB1-associated co-DEGs. ADARB1, adenosine deaminase RNA specific B1; co-DEGs, co-differentially expressed genes; LUSC, lung squamous cell carcinoma.

Association between clinical characteristic parameters and the expression of adenosine deaminase RNA specific B1 in lung squamous cell carcinoma.

Variable n Mean ± SD P-value
Pathologic T 0.433
  T1/T1a/T1b 100 8.148±0.924
  T2/T2a/T2b 252 8.103±1.035
  T3 48 8.367±0.967
  T4 19 8.155±1.232
Pathologic N 0.045
  N0 262 8.134±1.008
  N1 111 8.236±0.955
  N2 5 7.533±1.031
  N3 6 9.050±0.584
Pathologic M 0.012
  M0 357 8.113±0.996
  M1/M1a 6 7.576±0.607
  MX 50 8.511±1.081
Pathologic tumor stage 0.078
  I/IA/IB 211 8.116±0.985
  IIA/IIB 123 8.315±0.981
  IIIA/IIIB 76 8.013±1.122
  IV 6 7.576±0.607
Ethnicity 0.133
  White 297 8.190±1.033
  Black/African American 16 8.208±0.809
  Asian 9 8.888±1.028
Tobacco smoking history indicator 0.008
  Current reformed smoker for >15 years 71 8.404±0.991
  Current reformed smoker for ≤15 years 211 8.018±1.007
  Current reformed smoker, duration not specified 1 9.922±0.000
  Lifelong non-smoker 17 8.533±1.042
  Current smoker 112 8.137±0.977
Age 0.857
  ≤60 years 89 8.133±1.093
  >60 years 322 8.155±0.994
Karnofsky score 0.236
  0-70 47 7.939±1.233
  80 14 7.910±0.884
  90 22 8.173±0.948
  100 10 8.687±0.957
Eastern Cooperative Oncology Group score 0.079
  0 60 8.470±1.099
  1 71 8.208±0.978
  2 20 8.007±1.061
  3 3 7.211±0.597

Values in bold are significant.

Multivariate analysis of clinical data related to adenosine deaminase RNA specific B1 expression in lung squamous cell carcinoma.

Characteristic Type III sum of squares Degrees of freedom Mean square F-value P-value
Pathologic N 11.32 4 2.83 2.96 0.020
Pathologic M 11.50 2 5.75 6.02 0.003
Tobacco smoking history indicator   9.88 3 3.30 3.45 0.017

Association between the clinical characteristics and methylation site value of cg24063645 of adenosine deaminase RNA specific B1 in patients with lung squamous cell carcinoma.

Variable n Mean ± SD P-value
Sex 0.717
  Male 215 0.983±0.042
  Female   73 0.985±0.021
KRAS gene analysis indicator 0.760
  Yes   6 0.988±0.002
  No 197 0.983±0.038
EGFR mutation status 0.682
  Yes   15 0.987±0.002
  No 174 0.983±0.040
Treatment outcome: First course 0.718
  Complete remission/response   55 0.983±0.022
  Stable disease   2 0.989±0.001
Pathologic T 0.562
  T1/T1a/T1b   76 0.986±0.009
  T2/T2a/T2b 166 0.980±0.049
  T3   37 0.987±0.004
  T4   9 0.988±0.002
Pathologic N 0.117
  N0 179 0.984±0.029
  N1   79 0.985±0.014
  N2   24 0.967±0.099
  NX   6 0.984±0.004
Pathologic M 0.861
  M0 233 0.984±0.035
  M1/M1a   3 0.988±0.003
  MX   50 0.986±0.004
Tumor stage 0.919
  I/IA/IB 141 0.986±0.015
  IIA/IIB   96 0.986±0.013
  IIIA/IIIB   46 0.976±0.072
  IV   3 0.988±0.003
Ethnicity 0.878
  White 224 0.984±0.028
  Black/African American   10 0.988±0.002
  Asian   7 0.988±0.003
Karnofsky score 0.025
  0-70   29 0.988±0.002
  80   14 0.987±0.002
  90   18 0.985±0.004
  100   9 0.987±0.002
Age 0.341
  ≤60 years   59 0.987±0.003
  >60 years 221 0.982±0.043

Values in bold are significant. EGFR, epidermal growth factor receptor.